Peter Bains to replace Jonathan Hunt as CEO of Syngene
Peter Bains has over three decades of experience in the biotech and pharmaceutical industry
Peter Bains has over three decades of experience in the biotech and pharmaceutical industry
During the quarter, the company posted Revenue from operations at Rs. 5,269 crore as compared to Rs. 4,505 crore in Q3 FY25, posting a growth of 17 per cent
TFOS is indicated for the treatment of pulmonary arterial hypertension
During the quarter, US formulations revenue decreased by 2.3% YoY to Rs. 3,671 crore.
EMBLAVEOTM is the first and only monobactam/?-lactamase inhibitor combination antibiotic therapy approved by the USFDA
Cancer cases in India estimated to reach 1.57 million in 2025
This collaboration aims to bridge modern scientific research with traditional Ayurvedic wisdom, fostering innovative solutions that support holistic well-being
The stable raw materials prices, focused cost improvement initiatives and intensified customer acquisitions helped the company to improve its margin profile
International Meeting of World Pharmacopoeias serves as a vital platform to foster international collaboration in pharmacopoeial science and regulatory harmonization
Subscribe To Our Newsletter & Stay Updated